Back to News
Market Impact: 0.6
Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a transaction valued at up to US$2.35 billion. The acquisition is intended to strengthen Telix's position in global radiopharmaceuticals and radioisotopes, expanding its strategic capabilities in a key area of nuclear medicine.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
TLX0.72
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Paramount agrees invest $1.5 billion in domestic movies and create a board for editorial independence at CNN, CBS as part of deal for Warner Bros.
- Paramount and state AGs will settle lawsuit, allowing Warner Bros. merger to proceed, reports say
- +17% in a single session: This AI-picked stock catches a data-center breakout
- Paramount Set to Settle Lawsuits, Clearing Way for Warner Bros. Deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs